WO2007026895A1 - 尿路上皮ガンの検出用キットおよび方法 - Google Patents
尿路上皮ガンの検出用キットおよび方法 Download PDFInfo
- Publication number
- WO2007026895A1 WO2007026895A1 PCT/JP2006/317379 JP2006317379W WO2007026895A1 WO 2007026895 A1 WO2007026895 A1 WO 2007026895A1 JP 2006317379 W JP2006317379 W JP 2006317379W WO 2007026895 A1 WO2007026895 A1 WO 2007026895A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- cancer
- nucleic acid
- antibody
- gene
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
Definitions
- the present invention relates to a method for detecting urothelial cancer by measuring CXCL1 protein useful for detecting or diagnosing urothelial cancer, or expression of a gene encoding the protein.
- the present invention also relates to a diagnostic kit for cancer comprising a substance capable of binding to the protein or gene, which is used for detection of urothelial cancer.
- Urinary epithelial cancer is a general term for bladder cancer, renal pelvic cancer, ureteral cancer, etc., and these cancers are cancers of transitional epithelial cells of the urinary tract, and their properties are common. It is believed that there is. Urinary epithelial cancer is the most common urinary tract organ cancer after prostate cancer. In 2000, the Ministry of Health, Labor and Welfare Minister's Secretariat Statistics Information Department “Demographic Statistics” shows that only bladder cancer is Tang, 9765 males, 3243 females, 3459 males, 158 7 females. Renal cancer and ureteral cancer have relatively few deaths of 797 and 713 for both men and women, respectively.
- bladder cancer is more common in people over the age of 50, and men develop two to three times more frequently than women. Smokers are thought to be about 4 times more likely than non-smokers.
- Superficial papillary cancer is a relatively low-grade cancer that protrudes into the lumen of the bladder (the inner surface of the bladder) but has a shallow root surface.
- Nipple-like (cauliflower-like) with a narrow stem. Can be treated endoscopically, but more than half of patients relapse in the bladder. The depth of the cancer may extend below the mucosa, but does not reach the muscle layer of the bladder.
- invasive cancer is a highly malignant cancer that tends to invade deep into the bladder wall where the roots spread and may metastasize. Therefore, treatment that puts a heavy burden on the body, such as cystectomy, use of anticancer drugs, and radiation therapy, is necessary.
- bladder cancer The most common symptom of bladder cancer is painless hematuria. There are cases of bladder inflammation such as pain during urine and not refreshing after urination. Diagnosis uses urinalysis (cytology), radiography, and endoscope. However, there are no specific and sensitive tumor markers that can be used in blood and urine that are useful for early diagnosis, and they are often discovered by testing after the cancer has progressed. In addition, urothelial cancer that occurs in parts other than the bladder has the same properties. Therefore, the practical use of a simple detection method with a specific and sensitive tumor marker for urothelial cancer, particularly bladder cancer, is expected.
- Patent Document 1 JP 2004-337120
- Patent Document 2 JP-A-2004-248508
- Patent Document 3 JP 2002-238599
- Patent Document 4 JP-A-2004-61288
- Patent Document 5 Japanese Patent Laid-Open No. 7_309895
- Patent Document 6 JP 2000-131321 A
- An object of the present invention is to find a novel urothelial cancer tumor marker and provide a method capable of effectively detecting urothelial cancer, particularly bladder cancer.
- the present invention includes the following inventions.
- a method for detecting urothelial cancer comprising measuring in vitro CXCL1 protein or expression of a gene encoding the protein in a biological sample derived from a subject.
- the nucleic acid probe is a nucleic acid comprising the base sequence represented by SEQ ID NO: 1 or a variant thereof, a nucleic acid comprising a complementary sequence thereof, a nucleic acid hybridizing under stringent conditions with these nucleic acids, Or the method according to (10), comprising a fragment containing 15 or more consecutive bases thereof.
- the protein in the sample is immunologically measured, and the amount of the protein is compared to that in the control sample.
- a nucleic acid comprising the base sequence represented by SEQ ID NO: 1 or a variant thereof, a nucleic acid comprising its complementary sequence, a nucleic acid that hybridizes with these nucleic acids under stringent conditions, or 15 or more thereof
- a probe consisting of a fragment containing consecutive bases
- the expression level of the gene in the sample is measured, and the urinary epithelium is used as an indicator that the expression level increases compared to that of the control sample.
- the method according to any one of (1) to (5), (7), (8), (10) to (: 12), which comprises detecting cancer.
- urothelial cancer is also selected from a group force consisting of bladder cancer, renal pelvis cancer, ureteral cancer, and urethral cancer.
- the gene has the base sequence shown in SEQ ID NO: 1 or a mutant sequence thereof (1) to (5), (7), (8), (10) to (12 ), (14) to (: 17).
- a kit for diagnosing urothelial cancer comprising an antibody or a fragment thereof, or a chemically modified derivative thereof, which specifically binds to CXCL1 protein or a fragment thereof.
- Fragment force S of the protein including an epitope consisting of at least 8 amino acids
- the method further comprises a labeled secondary antibody that can bind to the antibody or fragment thereof (20) to (2 The kit according to any one of 4).
- a nucleic acid comprising the base sequence represented by SEQ ID NO: 1 or a variant sequence thereof, a nucleic acid comprising a complementary sequence thereof, a nucleic acid that hybridizes with these nucleic acids under stringent conditions, or a nucleic acid thereof
- a kit for diagnosing urothelial cancer comprising a fragment containing 15 or more consecutive bases, or a chemically modified derivative thereof.
- the nucleic acid has the base sequence shown in SEQ ID NO: 1 or a mutant sequence thereof.
- kits according to (27) or (28), wherein the urothelial cancer is selected from the group consisting of bladder cancer, renal pelvis cancer, ureteral cancer, and urethral cancer.
- nucleic acids nucleotides, polynucleotides, amino acids, peptides, polypeptides, proteins, etc. are indicated in “Guidelines for the creation of specifications including base sequences or amino acid sequences” (edited by the Japan Patent Office). ) And customary in the art
- CXCL1 Chemokine (C—X—C motif) ligand 1, GR ⁇ ichi, GRO-1, melanoma growth stimulating activity, alpha
- a protein consisting of 107 amino acids belonging to the chemokine family and having a molecular weight of about 1. kDa. This protein acts as a ligand for CXCR1 and CXCR2, 7-transmembrane receptors, and neutrophils and basophils expressing these receptors Causes migration of spheres, mast cells, etc. (Richmond, A et al., 1988, EMBO journal, Section 7, p. 2025-712033).
- nucleic acid is used to include both RNA and DNA.
- the DNA includes any of cDNA, genomic DNA, and synthetic DNA.
- the RNA includes any of total RNA, mRNA, rRNA, and synthetic RNA.
- the nucleic acid is used interchangeably with the polynucleotide.
- cDNA includes a full-length DNA strand of a sequence complementary to RNA generated by gene expression and a DNA fragment consisting of a partial sequence thereof.
- cDNA can be synthesized by RT-PCR (Reverse Transcriptase-Polymerase Chain Reaction) using RNA as a cage and using poly-T primers.
- gene refers not only to double-stranded DNA, but also to each single-stranded DNA such as a positive strand (or sense strand) or a complementary strand or an antisense strand constituting the same. Used with the intention of inclusion. The length is not particularly limited. Therefore, in this specification, unless otherwise specified, “gene” refers to double-stranded DNA including human genomic DNA, single-stranded DNA including cDNA (positive strand), and single-stranded DNA having a sequence complementary to the positive strand. DNA (complementary strand) and any of these fragments are included.
- the “gene” is not only a “gene” represented by a specific base sequence (or SEQ ID NO), but also a protein having a biological function equivalent to a protein encoded by these, for example, a homolog (ie, homolog), Variants such as splice variants and “genes” encoding derivatives are included.
- a “gene” encoding such a homologue, variant or derivative specifically, a base sequence that hybridizes with a complementary sequence of the base sequence represented by SEQ ID NO: 1 under the stringent conditions described later.
- the “gene” possessed can be mentioned.
- a homologue of a human-derived protein ie, a homolog
- a gene encoding the same can be exemplified by a protein or gene of another biological species corresponding to the protein or the human gene encoding the same.
- Protein or gene homozygous HomoloGene http://www.ncbi.nlm.nih.gov/homoloGene/
- a specific human amino acid or nucleotide sequence is represented by the BLAST program (Kariin, S. et al., Proceedings of the National Academic Sciences US A., 1993, 90th, p.
- the "gene” may include, for example, an expression control region, a code region, an exon, or an intron, without questioning whether the functional region is different.
- transcript refers to messenger RNA (mRNA) synthesized with a DNA sequence of a gene as a cage.
- RNA polymerase binds to a site called a promoter located upstream of the gene, and ribonucleotides are bound to the 3 'end so that it is complementary to the DNA base sequence.
- This mRNA includes not only the gene itself but also the entire sequence from the transcription start point to the end of the poly A sequence, including the expression control region, coding region, exon or intron.
- translation product refers to a protein synthesized based on the information regardless of whether or not the mRNA force splicing synthesized by transcription is modified or not.
- ribosome and messenger RNA are first bound, and then amino acids are linked according to the base sequence of mRNA to synthesize a protein.
- probe refers to RNA produced by gene expression, or RNA Nucleic acids used to specifically detect nucleic acids derived from and / or complementary nucleic acids thereto.
- primer includes continuous nucleic acids and Z or complementary nucleic acids that specifically recognize and amplify RNA produced by gene expression or nucleic acids derived therefrom. To do.
- complementary nucleic acid ⁇ complementary strand, reverse strand is a full-length nucleic acid sequence consisting of a base sequence defined by SEQ ID NO: or its partial partition ⁇ 1J (here, for convenience, this is the normal strand)
- the strong complementary strand is not limited to forming a complete complementary sequence with the base sequence of the target positive strand, but has a complementary relationship that can be hybridized with the target positive strand under stringent conditions. You may have.
- stringent conditions refers to conditions under which a probe hybridizes to its target sequence to a detectably greater extent (eg, at least twice background) than to other sequences. Say. Stringent conditions are sequence-dependent and depend on the environment in which the hybridization is performed. By controlling the stringency of the hybridization and / or wash conditions, target sequences that are 100% complementary to the probe can be identified.
- the term "mutant" refers to a natural variant, homologue, or degeneracy of the genetic code caused by polymorphism, mutation, alternative splicing during transcription, and the like. Or a mutation comprising one or more, preferably one or several base deletions, substitutions, additions or insertions in the base sequence represented by SEQ ID NO: 1 or a partial sequence thereof. Or about 80% or more, about 85% or more, and preferably about 90% with the base sequence or a partial sequence thereof. / o or more, more preferably about 95% or more, about 97% or more, about 98.
- nucleic acid that hybridizes under stringent conditions as defined above with a variant showing% identity of 0 or more, or about 99% or more, or a polynucleotide or oligonucleotide containing the nucleotide sequence or a partial sequence thereof
- a variant comprising a deletion, substitution, addition or insertion of one or more, preferably one or several amino acids in the amino acid sequence represented by SEQ ID NO: 2 or a partial sequence thereof, Or the amino acid About 80% or more, about 85% or more, preferably about 90% or more, more preferably about 95% or more, about 97% or more, about 98% or more, or about 99% or more% identity to the sequence or a partial sequence thereof It means the variant which shows.
- “several” means an integer of about 10, 9, 8, 7, 6, 5, 4, 3 or 2 or less.
- % identity can be determined by introducing a gap using the above-mentioned protein or gene search system by BLAST or FASTA (Karim, S. et al. 1993, Proceedings oi the National Academic Sciences U. 3 ⁇ 4 .A., 90, p. 5873-5877; Altschul, SF et al., 1990, Journal of Molecular Biology, 215, p. 403-410 Pearson, WR et al., 1988, Proceedings of the National Academic Sciences USA, Vol. 85, p.2444-244 8).
- the term "derivative” means, in the case of nucleic acid, a labeled derivative with a fluorophore, a radioisotope, etc., a modified nucleotide (for example, alkyl such as halogen and methyl, alkoxy such as methoxy, thio, Nucleotides containing groups such as carboxymethyl, biotinylated nucleotides, and nucleotides that have undergone base rearrangement, double bond saturation, deamination, substitution of oxygen molecules to sulfur molecules, etc.)
- chemical modifications such as acetylation, acylation, alkylation, phosphorylation, sulfation, glycosylation, piotin / avidination, labeling (eg, labels for enzymes, fluorophores, luminescent substances, etc.) Derivative means.
- the term "diagnosis or detection or determination kit” refers to the presence or absence of urothelial cancer, the degree of morbidity, the presence or absence of improvement, and the degree of improvement. It is used directly or indirectly to screen candidate substances useful for the prevention, amelioration or treatment of urothelial cancer.
- the "biological sample” to be detected and diagnosed refers to a sample (or specimen) in which the expression of the protein and Z or gene of the present invention changes as urothelial cancer develops.
- the sample includes urothelial tissue and surrounding lymph nodes, other organs suspected of metastasis, blood, serum, plasma, lymphocyte culture supernatant, urine, spinal fluid, saliva, sweat , Body fluids such as ascites, and cell or organ extracts.
- urinary tract epithelial cancer means a cancer that develops in the transitional epithelium in the kidney cup, renal pelvis, ureter, bladder, and urethra.
- urothelial cancer include bladder cancer, renal pelvis cancer, ureteral cancer, and urethral cancer, and the present invention is particularly preferably used for detection of bladder cancer.
- subject refers to an animal having a urothelial cancer, preferably a mammal, more preferably a human.
- urothelial cancer can be easily detected with high reliability. For example, it is possible to easily determine whether or not the patient has urothelial cancer simply by measuring the ratio of the CXCL1 concentration / creatine concentration in the urine of the patient. In this case, it is particularly effective for detecting invasive tumors.
- FIG. 1 Comparison of mRNA expression levels by RT-PCR measurement of CXCL1 in bladder cancer cell lines and normal urothelial epithelial cells.
- FIG. 2 CXCL1 tongue in culture supernatants of bladder cancer cell lines and normal urothelial cells Protein expression level.
- FIG. 3 CXCL1 protein expression in urine of bladder cancer patients.
- FIG. 4 Measurement of CXCL1 protein expression level in urine of bladder cancer patients.
- the white circles indicate the numerical values of each data, and the average value and standard error are indicated by + characters.
- * Indicates that there is a significant difference between healthy individuals (control) and early cancer patients (Ta) with a risk factor of P 001.
- + Indicates a significant difference between patients with early cancer and those with advanced cancer (T1 and above) with a risk factor of P ⁇ 0. 01
- FIG. 5 is an immunostaining diagram of CXCL1 protein expression in tissues of bladder cancer patients. Strong staining is seen in advanced cancer (PT2G3) and lymph node metastases. In contrast, no staining was observed in normal urothelial tissue (pTaGl).
- the present inventors have now confirmed that the protein whose expression is enhanced in cancer cells derived from bladder cancer patients compared to normal urothelial cells, Screening was performed by proteome analysis. As a result, it was found that the full length CXCL1 protein was detected more in the culture supernatant of cancer cells than in the culture supernatant of normal urothelial cells.
- normal urothelial cells are epithelial cells obtained from normal ureters of nephrectomized patients who do not suffer from urothelial cancer.
- the present inventors also measured the amount of CXCL1 protein in blood and urine before and after surgery for bladder cancer patients by an immunological method. The patient's blood and urine were found to be more highly detected than after bladder cancer removal.
- the present inventors further recovered total RNA expressed in cells derived from bladder cancer patients and normal urothelial cells, and expressed the expression level of the gene encoding CXCL1 in the total RNA by DNA array method and Measured by quantitative PCR, it was found that the amount of mRNA encoding CXCL1 was increased in cells derived from bladder cancer patients compared to normal cells.
- the present invention in one embodiment thereof, comprises measuring in vitro the CXC L1 protein in a biological sample derived from a subject, or the expression of a gene encoding the protein, and urothelial cancer Provide a method of detecting [0072]
- the presence or amount of the protein or the expression or expression level of the gene in a biological sample is measured.
- the target protein or gene in the present invention also includes mutants caused by the type of subject (for example, polymorphism depending on individuals, splice mutation, etc.
- the expression and expression level of a gene can be measured using a substance that can specifically bind to the protein or gene, such as an antibody or a nucleic acid probe described below. included.
- the antibody that can be used in the present invention recognizes the CXCL1 protein (preferably a protein having the amino acid coordination IJ of SEQ ID NO: 2) and specifically binds to the antibody, a fragment thereof, or a chemical modification Derivative (defined above).
- Antibodies include polyclonal antibodies, monoclonal antibodies, or antibody fragments such as Fab, Fab ', F (ab'), Fv, ScFv, etc.
- the antibody of the present invention is an antibody against one or more epitopes composed of at least 5, preferably at least 8 amino acids of the protein.
- a specific polyclonal antibody is obtained by a technique including, for example, passing an antiserum such as a rabbit immunized with a CXCL1 protein to a carrier such as agarose and collecting the IgG antibody bound to the column carrier. Can be produced.
- the monoclonal antibody can be obtained by a technique described later.
- a nucleic acid probe that can be used in the present invention hybridizes under stringent conditions with a nucleic acid comprising the nucleotide sequence represented by SEQ ID NO: 1 or a mutant sequence thereof, a nucleic acid comprising a complementary sequence thereof, or a nucleic acid thereof. Includes nucleic acids, or fragments containing 15 or more consecutive bases thereof, or chemically modified derivatives thereof (as defined above).
- the abundance of the protein or the expression level of the gene in a biological sample from a subject is measured. If the amount of the protein or the expression level of the gene is significantly increased compared to that of the control sample, it is determined that the subject is suffering from urothelial cancer.
- the control sample is, for example, a corresponding sample from a normal or healthy individual or an individual who does not have urothelial cancer, for example, body fluid such as blood and urine, urothelial tissue or cells, and the like.
- body fluid such as blood and urine, urothelial tissue or cells, and the like.
- mRNA is recovered from these samples by conventional methods, and is generated and amplified by quantitative RT-PCR.
- the amount of cDNA (which corresponds to the expression level of the target gene) can be determined, or the cells can be cultured and the concentration of CXCL1 protein in the culture supernatant can be measured
- the increase rate relative to the control sample is usually 2 times or more, preferably 3 times or more, more preferably 4 times or more, and most preferably 5 times or more. If the increase rate is 3 times or more, the reliability increases.
- the degree of increase can be determined by comparing the relative values with respect to, for example, a certain amount of a correction substance (for example, creatinine) based on only a comparison of measured actual values.
- urothelial cancer includes, for example, bladder cancer, renal pelvis cancer, ureteral cancer, urethral cancer, and the like.
- detection of bladder cancer was significantly more reliable in detecting invasive tumors than in superficial tumors. Therefore, the present invention will be more effective in detecting invasive tumors that are prone to metastasis among urothelial cancers.
- the method for detecting urothelial cancer of the present invention uses a primer or a probe for nucleic acid derived from a gene encoding a CXCL1 protein produced from a urothelial cancer cell in a sample. It includes measuring the expression level or immunologically measuring CXCL1 protein in a sample produced by urothelial cancer cells using an antibody.
- the method of the present invention makes it possible to distinguish between urothelial cancer patients and non-urothelial cancer patients who can only determine whether or not the subject has urothelial cancer.
- the expression level of a nucleic acid derived from a gene encoding a CXCL1 protein in a sample or the CXCL1 protein in the sample can be determined by quantifying the expression level of the urothelial cancer.
- the present invention provides a method for immunologically quantifying CXCL1 protein in a sample by using an antibody or fragment thereof that specifically binds to the CXCL1 protein or fragment thereof. It provides a method for detecting urothelial cancer represented by cancer.
- the present invention provides a nucleic acid comprising a nucleotide sequence encoding CXCL1 protein, a nucleic acid comprising a sequence complementary thereto, a nucleic acid that hybridizes with these nucleic acids under stringent conditions, or Use fragments of 15 or more bases of those nucleic acids
- the present invention provides a method for detecting urothelial cancer represented by bladder cancer by measuring the expression level of a gene encoding CXCL1 protein in a sample.
- the expression level of a gene encoding CXCL1 protein produced from urothelial cancer cells in a sample is measured using a nucleic acid as a primer or probe. The method of doing is mentioned.
- a nucleic acid that can be used for determining the presence and / or absence of urothelial cancer or for diagnosing urothelial cancer is a human-derived CXCL1 gene, its cognate Enables the qualitative and / or quantitative determination of the presence, expression level or abundance of the body, its transcript or cDNA, or its mutants or derivatives.
- the expression level of CXCL1 gene is significantly increased in urothelial cancer tissue as compared to non-cancerous tissue. Therefore, the composition of the present invention can be used effectively for measuring the expression level of CXCL1 gene in non-cancerous tissue and urothelial cancer tissue and comparing them.
- a nucleic acid that can be used in the present invention includes a nucleic acid comprising the base sequence represented by SEQ ID NO: 1 in a living tissue of a patient suffering from urothelial cancer, a complementary nucleic acid thereof, and a complementary nucleic acid to the base sequence.
- a nucleic acid that hybridizes with a DNA comprising a base sequence under stringent conditions, a complementary nucleic acid thereof, and one or more nucleic acids selected from a nucleic acid group containing 15 or more consecutive bases in the base sequence of those nucleic acid groups Includes combinations.
- the above-mentioned polynucleotide fragment is, for example, the total number of 15 to 30 consecutive bases J, 15 to 300 bases, 15 to 250 bases, 15 to 200 bases, 15 to : 150 bases, 15-: 140 bases, 15-: 130 bases, 15-: 120 bases, 15-: 110 bases, 15-: 100 bases, 15-90 bases, 15-80 bases, 15-70 bases, 15-60 bases, 15-50 bases, 15-40 bases, 15-30 bases or 15-25 bases; 25-total number of bases in the sequence, 25-300 bases, 25-250 bases, 25-200 bases, 25- : 150 bases, 25-: 140 bases, 25-: 130 bases, 25-: 120 bases, 25-: 110 bases, 25-: 100 bases, 25-90 bases, 25-80 bases, 25-70 bases 25 to 60 bases, 25 to 50 bases or 25 to 40 bases; 50 to the total number of bases in the sequence, 50 -300 bases, 50-250 bases, 50-200 bases;
- nucleic acids or fragments thereof used in the present invention may be DNA or RNA.
- the nucleic acid as the composition of the present invention can be prepared using a general technique such as a DNA recombination technique, a PCR method, or a method using a DNA / RNA automatic synthesizer.
- the present invention is also for urothelial cancer diagnosis (detection) comprising one or more of a nucleic acid, a variant thereof and / or a fragment thereof which can be used as a probe (and optionally a primer) in the above method.
- urothelial cancer diagnosis comprising one or more of a nucleic acid, a variant thereof and / or a fragment thereof which can be used as a probe (and optionally a primer) in the above method.
- Provide kit comprising one or more of a nucleic acid, a variant thereof and / or a fragment thereof which can be used as a probe (and optionally a primer) in the above method.
- the kit of the present invention preferably comprises one or more nucleic acids selected from the nucleic acids described above or a fragment thereof.
- the kit of the present invention comprises a nucleic acid comprising the base sequence represented by SEQ ID NO: 1, a nucleic acid comprising a complementary sequence thereof, a nucleic acid that hybridizes with these nucleic acids under stringent conditions, or a fragment of these nucleic acids.
- the nucleic acid comprises a nucleotide sequence represented by SEQ ID NO: 1.
- a nucleic acid comprising a complementary sequence thereof, a nucleic acid that hybridizes with these nucleic acids under stringent conditions, or a fragment containing 15 or more consecutive bases thereof.
- the fragment is 15 or more, preferably 30 or more, preferably 50 or more.
- it can be a nucleic acid containing 60 or more, for example 50 to 100, consecutive bases.
- kits of the present invention are merely examples, and all other various possible combinations are included in the present invention.
- nucleic acids, variants or fragments thereof contained in the kit of the present invention are packaged individually or in any combination in different containers.
- the nucleic acid as a probe contained in the kit of the present invention may be bound to a solid phase carrier.
- the carrier include a substrate such as a DNA microarray or a DNA chip.
- DNA microarrays and DNA chips containing the above nucleic acids are also within the scope of the present invention.
- nucleic acids that can be immobilized are all the nucleic acids of the present invention described above.
- nucleic acids can include one or more of the following nucleic acids or fragments thereof.
- a nucleic acid consisting of the base sequence represented by SEQ ID NO: 1, a variant thereof, or a fragment thereof containing 15 or more consecutive bases.
- a nucleic acid comprising the base sequence represented by SEQ ID NO: 1.
- a nucleic acid group that hybridizes under stringent conditions with DNA consisting of a base sequence complementary to the base sequence represented by SEQ ID NO: 1, or a fragment thereof containing 15 or more consecutive bases.
- a nucleic acid comprising 60 or more consecutive bases in each of the base sequence represented by SEQ ID NO: 1 or its complementary sequence.
- the solid-phased nucleic acid is genomic DNA, cDNA, RNA, synthetic DNA, synthetic RNA, misaligned, or single-stranded, double-stranded. But min.
- a method of immobilizing a previously prepared probe on a solid surface can be used.
- a nucleic acid into which a functional group has been introduced is synthesized, and oligonucleotides or polynucleotides are spotted on the surface of the surface-treated solid support and covalently bound (for example, JB
- the nuclear acid is covalently bonded to the surface-treated solid support via a spacer or a crosslinker.
- a method is also known in which polyacrylamide gel fragments are aligned on a glass surface and a synthetic nucleic acid is covalently bound thereto (G. Yershov et al., Proceedings of the National Academic Sciences USA, 1996, 94th page, p. 4913).
- an array of microelectrodes is prepared on a silica microarray, and an agarose permeation layer containing streptavidin is provided on the electrode as a reaction site, and this site is positively charged to immobilize the piotinated polynucleotide.
- an agarose permeation layer containing streptavidin is provided on the electrode as a reaction site, and this site is positively charged to immobilize the piotinated polynucleotide.
- the substrate of the DNA chip is not particularly limited as long as DNA can be solid-phased, and examples thereof include a slide glass, a silicon chip, a polymer chip, and a nylon membrane.
- these substrates are subjected to surface treatments such as the introduction of functional groups such as poly-L-lysine-coated kyamino groups and carboxyl groups.
- the solid phase immobilization method is not particularly limited as long as it is a commonly used method.
- a high-density dispenser for example, put a different gene solution in each well of a plate having many wells, pick up this solution with a pin (needle), and spot it on the substrate in order. By doing.
- genes are ejected from Nozunore and arranged at high speed on the substrate.
- a base bonded to a substrate is protected with a functional group that can be eliminated by light, and a mask is used to irradiate only the base at a specific site to desorb the functional group. Thereafter, the step of adding a base to the reaction solution and coupling with the base on the substrate is repeated.
- hybrida I See Chillon conditions include, but are not limited to, for example, 30 ° C ⁇ 50 ° C, 3 ⁇ 4 XS SC, 0. 1 ⁇ 0 5 0/0 in SDS:.! ⁇ 24B temple ⁇ Noble hybridization, more preferably at 40 ° C to 45 ° C, in 3.4 X SSC, 0.3% SDS:! ⁇ 24 hours of hybridization, and subsequent washing Including.
- washing conditions include conditions such as continuous washing at room temperature with a solution containing 233 and 0.1% SDS, and a 1 X SSC solution and a 0.2 X SSC solution.
- 1 X SSC is an aqueous solution (pH 7.2) containing 150 mM sodium chloride and 15 mM sodium citrate. It is desirable that the complementary strand maintain a hybridized state with the target positive strand even if washed under strong conditions.
- a complementary strand consisting of a base sequence that is completely complementary to the target positive strand base sequence, and a base sequence having at least 80% homology with the strand. Can be exemplified.
- Examples of stringent hybridization conditions when PCR is carried out using the polynucleotide fragment of the kit of the present invention as a primer include, for example, 10 mM Tris-HCL (pH 8.3), 50 mM KC1, 1 to
- a PCR buffer having a composition such as 2 mM MgCl may be used, and the melting temperature (Tm) calculated from the sequence of the primer may be 5 to 10 ° C for 15 seconds to 1 minute.
- Tm 2 X (number of adenine residues + number of thymine residues) + 4 X (number of guanine residues + number of cytosine residues)
- Another method for detecting urothelial cancer according to the present invention includes a method for measuring the presence or amount of CXCL1 protein produced from urothelial carcinoma cells in a sample using an antibody.
- an antibody that can be used to determine the presence and / or absence of urothelial cancer or to diagnose urothelial cancer is a human-derived CXCL1 gene, its cognate. Enables the qualitative and / or quantitative measurement of the expression level or abundance of the translation product of the body, or a variant or derivative thereof.
- the antibody that can be used in the present invention is not particularly limited as long as it specifically binds to CXCL1 protein or a fragment thereof.
- a monoclonal antibody that can be used as a monoclonal antibody or a polyclonal antibody is used. It is preferable to do this.
- the globulin type of the antibody of the present invention is not particularly limited as long as it has the above characteristics, and may be any of IgG, IgM, IgA, IgE, and IgD, but IgG and IgM are preferred.
- 20326 ⁇ l abl0375, Abeam
- polyclonal antibodies are also commercially available from Abeam.
- An antibody that specifically binds to the CX CL1 protein can also be produced by the method described below.
- a protein to be used as an immunogen is prepared.
- CXCL1 protein or a fragment thereof is used.
- the amino acid sequence (SEQ ID NO: 2) of CXCL1 protein that can be used as an immunogen in the present invention and the cDNA sequence (SEQ ID NO: 1) encoding the protein are listed in GenBank, respectively, with accession numbers NP_001502 and NM_001511. It has been published as Therefore, it is possible to synthesize CXCL1 protein fragments for use as immunogens by publicly known methods such as solid phase peptide synthesis using publicly available amino acid sequence information. it can.
- a carrier protein such as KLH or BSA.
- the CXCL1 protein uses information on the cDNA encoding the CXCL1 protein, It can be obtained by using a known DNA recombination technique.
- CDNA encoding CXCL1 protein can be prepared by cDNA cloning method. It is obtained by treating total RNA extracted from living tissue such as monocytes, melanoma cells, airway epithelial cells, keratinocytes, and alveolar macrophages that express the CXCL1 gene, which is a target in the present invention, with an oligo dT cellulose column.
- a cDNA library can be prepared from poly A (+) RNA by RT_PCR, and the desired cDNA clone can be obtained from this library by screening such as hybridization screening, expression screening, and antibody screening. If necessary, cDNA clones can be amplified by PCR.
- the probe or primer may be selected from among the contiguous sequences of 15 to 100 bases based on the base sequence shown in SEQ ID NO: 1 and synthesized.
- the cDNA cloning technique is described in, for example, Sambrook, J. & Russel, D., Molecular Cloning, A LAB ORATORY MANUAL, Cold Spring Harbor Laboratory Press, January 15, 2001, pp. 1.42 to 7.45. 2nd Section 8. 9. 8-8.
- the CXCL1 protein can be obtained by, for example, incorporating a cDNA clone obtained as described above into an expression vector, and culturing a prokaryotic or eukaryotic host cell transformed or transfected with the vector. Alternatively, it can be obtained from the culture supernatant.
- expression vectors plasmids derived from E.
- coli eg, pET21a, pGEX4T, pC118, pC119, pC18, pC19, etc.
- Bacillus subtilis eg, pUB110, pTP5, etc.
- plasmids derived from yeast eg, YEpl 3, YEp24, YCp50 and the like
- examples of phage DNA include ⁇ phage ( ⁇ gtl l, ⁇ , etc.).
- animal viruses such as vaccinia virus and insect virus vectors such as baculovirus can be used.
- CXCL1 cDNA To insert CXCL1 cDNA into a vector, first, the purified DNA is cleaved with an appropriate restriction enzyme, inserted into the appropriate vector restriction enzyme site or multiple cloning site, and ligated to the vector. Method is adopted.
- the vector contains the protein
- regulatory elements such as promoters, enhancers, polyadullation signals, ribosome binding sites, replication origins, terminators, selectable markers, etc. can be included.
- a fusion polypeptide in which a labeling peptide is attached to the C-terminus or N-terminus of the polypeptide may be used.
- Representative labeling peptides include histidine repeats of 6 to 10 residues, FLAG, myc peptide, GFP protein, etc.
- the force labeling peptide is not limited to these.
- DNA recombination techniques are described in Sambrook, J. & Russel, D. (above). A known DNA ligase is used to link the DNA fragment and the vector fragment.
- Host cells include prokaryotic cells such as bacteria (eg, Escherichia coli, Bacillus subtilis), yeast (eg, Saccharomyces * cerevisiae), insect cells (eg, Sf cells), mammalian cells (eg, C 0 S, CH 0, BHK) can be used.
- the method for introducing a recombinant vector into a host cell is not particularly limited as long as it is a method for introducing DNA into each host. For example, a method using calcium ions, a method using ribosomes, an electrovolution method, And microinjection method.
- the medium contains a carbon source, a nitrogen source, inorganic salts, and the like that can be assimilated by the microorganism.
- Either natural or synthetic media can be used as long as the culture can be carried out efficiently.
- the culture is usually carried out at 37 ° C for 6 to 24 hours under aerobic conditions such as shaking culture or aeration and agitation culture.
- the pH is kept near neutral.
- the pH is adjusted using an inorganic or organic acid, alkaline solution, or the like.
- an antibiotic such as ampicillin or tetracycline may be added to the medium as necessary.
- the culture supernatant or the protein settled in the cell is recovered after culturing in a medium suitable for each cell.
- the medium may or may not contain serum, but culture in a serum-free medium is more desirable.
- CXCL1 protein is produced in cells or cells, the protein is extracted by disrupting the cells or cells.
- CXCL1 protein is produced outside the cells or cells, use the culture solution as it is, or remove the cells or cells by centrifugation or the like.
- examples of the purification method include methods including ultrafiltration, salting out, gel filtration, ion exchange chromatography and the like.
- the antibody that recognizes the protein thus obtained can specifically bind to the protein via the antigen-binding site of the antibody.
- CXCL1 protein or a fragment thereof, a mutant protein or a fusion protein thereof can be used as an immunogen for producing antibodies that are immunoreactive with each other.
- proteins, fragments, mutants, fusion proteins and the like contain antigenic determinants or epitopes that elicit antibody formation, but these antigenic determinants or epitopes may be linear, A higher order structure (intermittent) may be used.
- the antigenic determinant or epitope can be identified by any method known in the art.
- Antibodies of all embodiments are induced by the protein of the present invention. Once all or part of the protein or epitope has been isolated, both polyclonal and monoclonal antibodies can be prepared using conventional techniques. Examples of the method include those described in Kennet Osamu), Monoclonal Antibodies, Hybridomas: A New Division in Biological Analyzes, Pienum Press, New York, 1980.
- the obtained protein is dissolved in a buffer to prepare an immunogen.
- an adjuvant may be added for effective immunization.
- Adjuvants include commercially available complete Freund's adjuvant, incomplete Freund's adjuvant, aluminum hydroxide Alum, muramyl peptide, etc., and any of these may be mixed.
- the immunogen obtained as described above is administered to mammals such as rats, mice (for example, Balb / c of inbred mice), and rabbits.
- the single dose of the immunogen is appropriately determined according to the type of immunized animal, the route of administration, etc., and is about 50 to 20 O x g per animal.
- Immunization is performed mainly by injecting an immunogen subcutaneously or intraperitoneally.
- the immunization interval is not particularly limited, and after the first immunization, booster immunization is performed at intervals of several days to several weeks, preferably:! To 4 weeks, 2 to 10 times, preferably 3 to 4 times.
- the antibody titer in the serum of the immunized animal is repeatedly measured by ELISA (Enzyme-Linked Immuno Sor bent Assay) method.
- ELISA Enzyme-Linked Immuno Sor bent Assay
- the immunogen is intravenously or intraperitoneally
- antibody-producing cells are collected 2 to 5 days, preferably 3 days after the last immunization day. Examples of antibody-producing cells include spleen cells, lymph node cells, peripheral blood cells, etc., but spleen cells or local lymph node cells are preferred.
- a hybridoma cell line that produces a monoclonal antibody specific for each protein is also provided.
- Such hyperpridoma can be produced and identified by conventional techniques.
- One method for producing such a hyperidoma cell line is to immunize an animal with the protein of the invention, collect spleen cells from the immunized animal, fuse the spleen cells to a myeloma cell line, and Generating a hyperidoma cell and identifying a hyperidoma cell line that produces a monoclonal antibody that binds to the enzyme.
- a myeloma cell line to be fused with an antibody-producing cell a generally available cell line of an animal such as a mouse can be used.
- the cell line used has drug selectivity and cannot survive in a HAT selection medium (including hypoxanthine, aminopterin, thymine) in an unfused state, but can survive only in a state fused with antibody-producing cells. Those having properties are preferred.
- the cell line is preferably derived from an animal of the same species as the immunized animal. Specific examples of myeloma cell lines are derived from BALB / c mice P3X63_Ag. 8 strain (ATCC TIB9) which is a hypoxanthine guanine 'phosphoribosyl' transferase (HGPRT) deficient cell line.
- HGPRT hypoxanthine guanine 'phosphoribosyl' transferase
- the myeloma cell line and antibody-producing cells are fused.
- cell fusion antibody-producing cells and myeloma cell lines are mixed at a ratio of 1 ::! To 20: 1 in animal cell culture media such as serum-free DMEM, RPMI-1640 media, The fusion reaction is performed in the presence of a cell fusion promoter.
- a cell fusion promoter polyethylene glycol having an average molecular weight of 1500 to 4000 daltons can be used at a concentration of about 10 to 80%.
- an adjuvant such as dimethyl sulfoxide may be used in combination in order to increase the fusion efficiency.
- the antibody-producing cells and the myeloma cell line can be fused using a commercially available cell fusion device using electrical stimulation (for example, electoral position).
- the target hyperidoma is selected from the cells after cell fusion treatment.
- the cell suspension is appropriately diluted with, for example, RPMI-1640 medium containing fetal bovine serum, and then plated on a microtiter plate at about 2 million cells / well, and a selective medium is added to each well. Cultivation is performed by appropriately changing the selection medium.
- the culture temperature is 20 to 40 ° C, preferably about 37 ° C.
- myeloma cells are HGPRT-deficient strain or thymidine kinase-deficient strain, cells that have antibody-producing ability and myeloma cells can be obtained by using hypoxanthine'aminopterin'thymidine-containing selective medium (HAT medium). Only strains of high-pridoma can be selectively cultured and propagated. As a result, cells that grow from about 14 days after the start of culturing in the selective medium can be obtained as a hyperidoma.
- HAT medium hypoxanthine'
- the culture supernatant of the proliferated hyperidoma is screened for the presence of the antibody of interest.
- Hypridoma screening is not particularly limited as long as it follows a normal method. For example, a portion of the culture supernatant contained in wells grown as wild or hybridoma is collected, and enzyme immunoassay (EIA: Enzyme Immuno Assay and ELISA), radioimmunoassay (RIA: Radio Immuno Assay), etc. Can be done. Cloning of the fused cells is carried out by limiting dilution or the like, and finally, a hyperidoma that is a monoclonal antibody-producing cell is established.
- EIA Enzyme Immuno Assay and ELISA
- RIA Radio Immuno Assay
- the hyperidoma of the present invention is stable in culture in a basic medium such as RPMI-1640 or DMEM. It produces and secretes monoclonal antibodies that specifically react with CXCL1 protein derived from urothelial cancer.
- Monoclonal antibodies can be recovered by conventional techniques. That is, as a method for collecting a monoclonal antibody from the established hybridoma, a normal cell culture method or ascites formation method can be employed. In the cell culture method, Hypridoma is cultured in an animal cell culture medium such as RPMI-1640 medium, MEM medium or serum-free medium containing 10% ushi fetal serum under normal conditions (for example, 37 ° C, 5% CO 2). Concentration) 2 ⁇ : 10 days
- the monoclonal antibodies of the present invention include chimeric antibodies, for example, humanized forms of murine monoclonal antibodies.
- the present invention also provides an antigen-binding fragment of the above antibody. Examples of antigen-binding fragments that can be produced by conventional techniques include Fab and F (ab ') fragments
- Antibody fragments and derivatives that can be produced by genetic engineering techniques are also provided.
- the antibody of the present invention can be used in an assay for detecting the presence of the polypeptide of the present invention or a (poly) peptide fragment thereof both in vitro and in vivo.
- the antibodies of the present invention can also be used to purify proteins or protein fragments by immunoaffinity chromatography.
- the method of the present invention is preferably any of a measurement method using the above-described antibody of the present invention, that is, an immunological measurement method, or a method of measuring the expression level of a gene encoding CXCL1 protein.
- immunological methods include enzyme immunoassay (ELISA, EIA), fluorescence immunoassay, radioimmunoassay (RIA), luminescence immunoassay, immunoturbidimetric method, latex agglutination, latex Examples include turbidimetry, hemagglutination, particle agglutination, or Western plotting.
- Quantitative RT-PCR method DNA array method, Northern blot method, Northern hybridization method, Southern blot method, Southern hybridization method can be used to measure the expression level of gene-derived nucleic acid. Law.
- a sample to be tested may be a biological sample that may contain CXCL1 protein derived from urothelial ganglia or a nucleic acid derived from a gene encoding the protein. If it is not particularly limited.
- the measured value of CXCL1 protein obtained from a body fluid sample such as urine, blood, plasma, and serum is useful as an index of urothelial cancer.
- the urothelial cancer detection method of the present invention is very useful as a simple detection method because it can be detected not only in cancer tissues but also in blood and urine.
- the protein detection method of the present invention is carried out by an immunoassay using a label such as an enzyme immunoassay, a fluorescence immunoassay, a radioimmunoassay, or a luminescence immunoassay
- a label such as an enzyme immunoassay, a fluorescence immunoassay, a radioimmunoassay, or a luminescence immunoassay
- the antibody of the present invention It is preferable to immobilize the components in the sample or to immobilize the components in the sample and perform their immunological reaction.
- solid phase carrier polystyrene, polycarbonate, polytoluene toluene, polypropylene, polyethylene, poly salt bulbu, nylon, polymetatalylate, latex, gelatin, agarose, cellulose, sepharose, glass, metal, ceramics or Beads, microplates, test tubes, sticks or test pieces made of magnetic materials (test strips)
- An insoluble carrier having a shape such as (a) can be used.
- the solid phase can be formed by binding the solid phase carrier and the antibody or sample component of the present invention according to a known method such as a physical adsorption method, a chemical binding method, or a combination thereof.
- the antibody of the present invention is labeled in order to easily detect the reaction between the antibody of the present invention and the CX CL1 protein derived from urothelial cancer cells in a sample.
- the reaction is detected directly or indirectly by using a labeled secondary antibody.
- it is preferable to use the latter indirect detection (for example, a sand switch method) in terms of sensitivity.
- labeling substance in the case of enzyme immunoassay, peroxidase (POD), alkaline phosphatase, ⁇ -galactosidase, urease, catalase, gnorecosidase, lactate dehydrogenase, amylase or piotin avidin complex, etc.
- POD peroxidase
- fluorescence immunoassay fluorescein isothiocyanate, tetramethylrhodamine sothiocyanate, substituted rhodamine isothiocyanate, dichlorotriazine isothiocyanate, Alexa or AlexaFluoro, etc.
- tritium iodine 125, iodine 131 or the like can be used.
- NADH—, FMNH 2 —, luciferase system, luminol hydrogen peroxide POD system, acrylidine ester system, dioxetane compound system, etc. can be used for the luminescence immunoassay.
- the labeling substance and the antibody are bound by a known method such as the dartal aldehyde method, the maleimide method, the pyridinoresisulfide method or the periodic acid method.
- a known method such as the dartal aldehyde method, the maleimide method, the pyridinoresisulfide method or the periodic acid method.
- known methods such as the chloramine T method and the Bolton Hunter method can be used.
- the measurement can be performed by a known method (Current protocols in Protein Sciences, 1995, John Wiley & Sons Inc., Current protocols in Immunology, 2001, John Wiley & Sons Inc.).
- the components in the sample are immobilized and brought into contact with the labeled antibody of the present invention to form a CXCL1 protein-antibody of the present invention complex.
- Unbound labeled antibody can be washed and separated, and the amount of CXCL1 protein in the sample can be measured from the amount of bound labeled antibody or the amount of unbound labeled antibody.
- a labeled secondary antibody is used, the antibody of the present invention is reacted with a sample (primary reaction), and further, a labeled secondary antibody is reacted (secondary reaction).
- the primary reaction and the secondary reaction may be performed in the reverse order, may be performed simultaneously, or may be performed at different times.
- the primary reaction and secondary reaction form a complex of immobilized CXCL1 protein-antibody of the present invention with a single labeled secondary antibody, or a solid phase of immobilized antibody of the present invention with one CXCL1 protein and a labeled secondary antibody.
- the unbound labeled secondary antibody can be washed and separated, and the amount of CXCL1 protein in the sample can be measured from the amount of bound labeled secondary antibody or the amount of unbound labeled secondary antibody.
- a substrate is reacted with a labeled enzyme under the optimum conditions, and the amount of the reaction product is measured by an optical method or the like.
- fluorescence immunoassay the fluorescence intensity by the fluorescent substance label is measured.
- radioimmunoassay the amount of radioactivity by the radioactive substance label is measured.
- luminescence immunoassay measure the amount of luminescence by the luminescence reaction system.
- immune complex aggregates such as immunoturbidimetry, latex agglutination, latex turbidimetry, erythrocyte agglutination or particle agglutination are generated, and the transmitted light and scattered light are optically transmitted.
- a phosphate buffer solution, a glycine buffer solution, a Tris buffer solution or a Good buffer solution can be used as the solvent, and polyethylene glycol or the like can be used.
- reaction accelerators and non-specific reaction inhibitors may be included in the reaction system.
- the antibody of the present invention is immobilized on an insoluble carrier as a primary antibody.
- the solid phase surface on which the antigen is not adsorbed is blocked with a protein unrelated to the antigen (eg, baby serum, rabbit serum albumin, gelatin).
- a protein unrelated to the antigen eg, baby serum, rabbit serum albumin, gelatin.
- the immobilized primary antibody is brought into contact with the test sample.
- a labeled secondary antibody that reacts with the CXCL1 protein at a site different from the primary antibody is contacted, and a signal from the label is detected.
- second antibody that reacts with the CXCL1 protein at a site different from the primary antibody refers to the type of immunogen that is not particularly limited as long as it recognizes sites other than the binding site between the primary antibody and CXCL1 protein.
- polyclonal antibody, antiserum, monoclonal anti can be used in any form of the body (Fab, F (ab '), Fab, Fv, ScF
- V etc. can also be used.
- multiple types of monoclonal antibodies may be used as secondary antibodies.
- the antibody of the present invention is labeled to give a secondary antibody, and an antibody that reacts with the CXCL1 protein at a site different from the antibody of the present invention is immobilized on an insoluble carrier as a primary antibody.
- the immobilized primary antibody may be brought into contact with a test sample, and then the antibody of the present invention labeled as a secondary antibody may be contacted to detect a signal from the label.
- the antibody of the present invention specifically reacts with CXCL1 protein derived from urothelial cancer cells, and thus can be used as a diagnostic agent for cancer.
- the diagnostic agent of the present invention contains the antibody of the present invention, and therefore, using the diagnostic agent of the present invention, the urinary tract contained in a sample collected from an individual force suspected of suffering from urothelial cancer. By detecting CXCL1 protein derived from skin cancer cells, it is possible to diagnose morbidity of urothelial cancer in the individual.
- the diagnostic agent of the present invention can be used in any means as long as it is a means for performing an immunological measurement.
- the immunochromatographic test strip known in the art can be used. By using in combination with simple means, cancer can be diagnosed more easily and quickly.
- the immunochromatographic test strip includes, for example, a sample receiving portion made of a material that easily absorbs a sample, a reagent portion containing the diagnostic agent of the present invention, a developing portion where a reaction product of the sample and the diagnostic agent moves, and a developing strip.
- the labeling part for coloring the reaction product, the presentation part for developing the colored reaction product, etc. can be configured in the same manner as the pregnancy diagnostic drug.
- the sample receiving portion absorbs the sample and causes the sample to reach the reagent portion.
- a reaction between the CXCL1 protein derived from urothelial cancer cells in the sample and the antibody of the present invention occurs, and the reacted complex moves through the development part and reaches the labeling part.
- the labeling part when the reaction between the reaction complex and the labeled secondary antibody occurs, and the reaction product with the labeled secondary antibody expands to the presentation part, a coloring power S is recognized.
- the immunochromatographic test strips can be used for monitoring at home because they do not give the user any pain or danger due to reagent use.
- Treatment surgical It can be used to prevent metastasis and recurrence.
- this test strip can be mass-produced at low cost by a manufacturing method as described in, for example, JP-A-10-54830.
- the diagnostic agent of the present invention in combination with a diagnostic agent for a known tumor marker of urothelial cancer, a more reliable diagnosis can be made.
- the present invention also relates to a diagnostic kit for urothelial cancer comprising an antibody or a fragment thereof that specifically reacts with CXCL1 protein or a fragment thereof.
- the antibody may be bound to the solid phase carrier as described above.
- the kit of the present invention may contain a labeled secondary antibody, a carrier, a washing buffer, a sample diluent, an enzyme substrate, a reaction stop solution, a purified CXCL1 protein as a standard substance, and the like.
- Normal urothelial cells were obtained from normal ureters from patients with nephrectomy. Urinary epithelial cells extracted from normal ureters were cultured in a 10 cm culture dish using Defined KSFM medium (Scriven, S. D. et al., 1997, Journal of Urology, 158, p. 1147-1152). 90 urothelial cells cultured in 4 culture dishes with a diameter of 10 cm. When it became / o confluent, it was washed 3 times with PBS (-), and then the medium was changed to RPMI1640 medium without serum and cultured for 24 hours, and the culture supernatant was collected.
- This culture supernatant was treated by ultracentrifugation (150,000 g, 30 minutes, 4 ° C) to remove the precipitate, and then the supernatant was concentrated by centrifugation using Amicon Ultra-15 (Millipore). (4,000 g, 20 minutes, 4 ° C). As a result, 1 mg of protein was extracted from 40 mL of the cultured cell supernatant.
- Bladder cancer cell lines (RT112, 5637, T24, and EJ) were cultured with RPMI1640 containing 10% urine fetal serum, and normal urothelial epithelial cells were cultured with defined-KSFM.
- Total RNA was prepared from these cells using Trizol reagent (Invitrogen) and RNeasy Mini kit (Qiagen) according to the recommended protocol.
- CDNA was synthesized from TotalRN A 3 microg using First-Strand cDNA sysnthesis kit (Amersham Biosciences). Using these cDNAs as templates, primers for CXCL1, one of the growth factors found from proteome analysis, and its receptor, CXCR2, were designed, and gene expression was determined by RT-PCR.
- agarose gel electrophoresis with molecular weight as an index (Fig. 1).
- Hi-Lo DNA Marker (BIONEXUS) was used as a molecular weight marker.
- CXCL1 mRNA expression was highly expressed in 5637 and T24, which are cell lines derived from invasive bladder cancer. Although expression was detected in normal tissues, it was found to be less severe than cell lines derived from invasive cancer.
- Bladder cancer cell lines (5637, T24) were each RPMI1 640 containing 10% urine fetal serum, and normal urothelial cells were defined--cultured with KSFM. Each cell was cultured in a 96-well plate for 24 hours, and the culture medium was exchanged when the cells were almost confluent. Furthermore, the culture supernatant was collected after 24 hours. The CXCL1 protein concentration in each culture supernatant was measured using Human GRO alpha / CXCLl Quantikine ELISA kit (R & D Systems).
- CXCL1 was not detected in the culture supernatant of normal urothelial cells, but it was a high concentration of about 5 to 2 Ong / mL or more in the culture supernatant of 5637, T24 derived from invasive cancer. CXCL1 was detected ( Figure 2).
- a urine sample was obtained from 3 patients with invasive bladder cancer and 1 healthy control, and the urinary CXC L1 protein concentration was measured using Human GR0 alpha / CXCLl Quantikine ELISA kit (R & D Systems). In each sample, urine Creathun concentration When the CXCL1 protein concentration was corrected using the degree of urine, a higher urinary CXCL1 protein concentration was detected in bladder cancer patients than in healthy controls (FIG. 3).
- Urine samples were obtained from 32 early-stage (Ta) bladder cancer patients, 35 advanced (T1 or higher) bladder cancer patients and 40 healthy controls, and the urinary CXCL1 protein concentration was determined using Human GR ⁇ alpha / CXCLl. Measurement was performed using Quantikine ELISA kit (R & D Systems). Higher urinary CXCL1 protein levels were detected in patients with early and advanced bladder cancer than in healthy controls ( Figure 4).
- the expression or expression level of the CXCL1 gene in the urothelial tissue or cells using the above-described antibody or nucleic acid probe is measured and compared with a control. It is possible to effectively detect early or advanced urothelial cancers such as bladder cancer, using as an index the detection or increase in the expression level.
- the present invention it is possible to effectively detect urothelial cancer by a simple and inexpensive method. Therefore, early detection, diagnosis and treatment of urothelial cancer are possible.
- the method of the present invention enables non-invasive detection of urothelial cancer using patient urine, so that urothelial cancer can be detected easily and quickly.
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002621060A CA2621060A1 (en) | 2005-09-02 | 2006-09-01 | Kit and method for detection of urothelial cancer |
CN2006800394581A CN101297046B (zh) | 2005-09-02 | 2006-09-01 | 用于检测尿路上皮癌的试剂盒及方法 |
US11/991,184 US7910316B2 (en) | 2005-09-02 | 2006-09-01 | Kit and method for detecting urothelial cancer |
JP2007533367A JP5078015B2 (ja) | 2005-09-02 | 2006-09-01 | 尿路上皮ガンの検出用キットおよび方法 |
EP06797321A EP1930445B1 (en) | 2005-09-02 | 2006-09-01 | Kit and method for detection of urothelial cancer |
DE602006013333T DE602006013333D1 (de) | 2005-09-02 | 2006-09-01 | Kit und verfahren zum nachweis von urothelkarzinom |
KR1020087007943A KR101393144B1 (ko) | 2005-09-02 | 2008-04-01 | 요로상피암의 검출용 키트 및 방법 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005-255370 | 2005-09-02 | ||
JP2005255370 | 2005-09-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007026895A1 true WO2007026895A1 (ja) | 2007-03-08 |
Family
ID=37808979
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/317379 WO2007026895A1 (ja) | 2005-09-02 | 2006-09-01 | 尿路上皮ガンの検出用キットおよび方法 |
Country Status (10)
Country | Link |
---|---|
US (1) | US7910316B2 (ja) |
EP (1) | EP1930445B1 (ja) |
JP (1) | JP5078015B2 (ja) |
KR (1) | KR101393144B1 (ja) |
CN (1) | CN101297046B (ja) |
AT (1) | ATE462803T1 (ja) |
CA (1) | CA2621060A1 (ja) |
DE (1) | DE602006013333D1 (ja) |
ES (1) | ES2343276T3 (ja) |
WO (1) | WO2007026895A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010050554A1 (ja) | 2008-10-31 | 2010-05-06 | 東レ株式会社 | ヒトcxcl1タンパク質の免疫学的測定方法 |
WO2011109810A2 (en) * | 2010-03-05 | 2011-09-09 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Methods of predicting high grade gliomas using senescence associated genes |
WO2020071489A1 (ja) * | 2018-10-04 | 2020-04-09 | 国立大学法人大阪大学 | 尿路上皮がんを検査する方法 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9499864B2 (en) | 2003-11-03 | 2016-11-22 | Aab Patent Holding Aps | Expression of FABP4 and other genes associated with bladder cancer progression |
EP2166358A1 (en) * | 2008-09-17 | 2010-03-24 | Fundacio Institut de Recerca de l'Hospital Universitari Vall d'Hebron | Differential diagnostic biomarkers of stroke mimicking conditions and methods of use thereof |
NZ592552A (en) * | 2008-11-22 | 2013-12-20 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
CN108245497A (zh) * | 2009-08-25 | 2018-07-06 | 博格有限责任公司 | 利用外代谢转换剂(辅酶q10)治疗肉瘤的方法 |
NZ589251A (en) * | 2010-11-12 | 2014-07-25 | Pacific Edge Ltd | Novel marker for detection of bladder cancer |
WO2013101611A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Molecular Inc. | Materials and methods for diagnosis of bladder cancer and monitoring recurrence thereof |
JP6281873B2 (ja) * | 2012-10-17 | 2018-02-21 | 公立大学法人奈良県立医科大学 | 新規癌マーカーおよびその利用 |
CN105505941A (zh) * | 2016-01-21 | 2016-04-20 | 中国人民解放军第四军医大学 | Cxcl1的适配体在制备检测上尿路上皮癌试剂中的应用 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07309895A (ja) | 1994-05-20 | 1995-11-28 | Idemitsu Kosan Co Ltd | 新規タンパク質、その検出方法及び診断薬 |
JPH1054830A (ja) | 1996-08-12 | 1998-02-24 | Omomo Souuemon | テストストリップの製造システム |
JP2000131321A (ja) | 1998-10-28 | 2000-05-12 | Igaku Seibutsugaku Kenkyusho:Kk | 膀胱癌患者の予後診断薬 |
JP2002238599A (ja) | 2001-02-21 | 2002-08-27 | Yoshihiko Funae | 膀胱癌の診断方法および診断キット |
JP2004061288A (ja) | 2002-07-29 | 2004-02-26 | Fukuyama Rinsho Kensa Center:Kk | 膀胱癌の検査判定方法 |
JP2004248508A (ja) | 2002-09-30 | 2004-09-09 | Chi Mei Foundation Medical Center | 膀胱癌に対する分子マーカーとしてのhurp遺伝子 |
JP2004337120A (ja) | 2003-05-19 | 2004-12-02 | Chang Gung Univ | 膀胱癌再発検査方法 |
WO2004108899A2 (en) * | 2003-06-04 | 2004-12-16 | The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Pni microarray and uses |
WO2004112589A2 (en) * | 2003-06-20 | 2004-12-29 | Genenews, Inc. | Method for the detection of gene transcripts in blood and uses thereof |
JP2005255370A (ja) | 2004-03-15 | 2005-09-22 | Mitsubishi Electric Corp | エレベーターの制御装置 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030190602A1 (en) * | 2001-03-12 | 2003-10-09 | Monogen, Inc. | Cell-based detection and differentiation of disease states |
US20060188889A1 (en) | 2003-11-04 | 2006-08-24 | Christopher Burgess | Use of differentially expressed nucleic acid sequences as biomarkers for cancer |
-
2006
- 2006-09-01 EP EP06797321A patent/EP1930445B1/en not_active Not-in-force
- 2006-09-01 JP JP2007533367A patent/JP5078015B2/ja not_active Expired - Fee Related
- 2006-09-01 WO PCT/JP2006/317379 patent/WO2007026895A1/ja active Search and Examination
- 2006-09-01 CN CN2006800394581A patent/CN101297046B/zh not_active Expired - Fee Related
- 2006-09-01 ES ES06797321T patent/ES2343276T3/es active Active
- 2006-09-01 US US11/991,184 patent/US7910316B2/en not_active Expired - Fee Related
- 2006-09-01 DE DE602006013333T patent/DE602006013333D1/de active Active
- 2006-09-01 CA CA002621060A patent/CA2621060A1/en not_active Abandoned
- 2006-09-01 AT AT06797321T patent/ATE462803T1/de not_active IP Right Cessation
-
2008
- 2008-04-01 KR KR1020087007943A patent/KR101393144B1/ko not_active IP Right Cessation
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07309895A (ja) | 1994-05-20 | 1995-11-28 | Idemitsu Kosan Co Ltd | 新規タンパク質、その検出方法及び診断薬 |
JPH1054830A (ja) | 1996-08-12 | 1998-02-24 | Omomo Souuemon | テストストリップの製造システム |
JP2000131321A (ja) | 1998-10-28 | 2000-05-12 | Igaku Seibutsugaku Kenkyusho:Kk | 膀胱癌患者の予後診断薬 |
JP2002238599A (ja) | 2001-02-21 | 2002-08-27 | Yoshihiko Funae | 膀胱癌の診断方法および診断キット |
JP2004061288A (ja) | 2002-07-29 | 2004-02-26 | Fukuyama Rinsho Kensa Center:Kk | 膀胱癌の検査判定方法 |
JP2004248508A (ja) | 2002-09-30 | 2004-09-09 | Chi Mei Foundation Medical Center | 膀胱癌に対する分子マーカーとしてのhurp遺伝子 |
JP2004337120A (ja) | 2003-05-19 | 2004-12-02 | Chang Gung Univ | 膀胱癌再発検査方法 |
WO2004108899A2 (en) * | 2003-06-04 | 2004-12-16 | The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Pni microarray and uses |
WO2004112589A2 (en) * | 2003-06-20 | 2004-12-29 | Genenews, Inc. | Method for the detection of gene transcripts in blood and uses thereof |
JP2005255370A (ja) | 2004-03-15 | 2005-09-22 | Mitsubishi Electric Corp | エレベーターの制御装置 |
Non-Patent Citations (22)
Title |
---|
"Current protocols in Immunology", 2001, JOHN WILEY & SONS INC. |
"Current protocols in Protein Sciences", 1995, JOHN WILEY & SONS INC. |
"Monoclonal Antibodies, Hybridomas: A New Dimension in Biological Analyses", 1980, PLENUM PRESS |
ALEXANDROFF A.B. ET AL.: "Role for CD40-CD40 ligand interactions in the immune response to solid tumours", MOLECULAR IMMUNOLOGY, vol. 37, no. 9, 2000, pages 515 - 526, XP009076194 * |
ALTSCHUL, S. F. ET AL., JOURNAL OF MOLECULAR BIOLOGY, vol. 215, 1990, pages 403 - 410 |
ANISOWICZ, A. ET AL., PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, USA, vol. 84, 1987, pages 7188 - 7192 |
DATABASE NCBI [online] 28 July 2005 (2005-07-28), STRAUSBERG R.L. ET AL., XP003010021, Database accession no. (BC011976) * |
G YERSHOV ET AL., PROCEEDINGS OF THE NATIONAL ACADEMIC SCIENCES, U.S.A., vol. 94, 1996, pages 4913 |
IGARASHI T. ET AL.: "Jingan ni okeru IL-8/GROalpha mRNA no Hatsugen", BIOTHERAPY, vol. 12, no. 5, 30 May 1998 (1998-05-30), pages 632 - 634, XP003010019 * |
J. B. LAMTURE ET AL., NUCLEIC. ACIDS. RESEARCH, vol. 22, 1994, pages 2121 - 2125 |
KARLIN, S. ET AL., PROCEEDINGS OF THE NATIONAL ACADEMIC SCIENCES, U.S.A., vol. 90, 1993, pages 5873 - 5877 |
KARLIN, S. ET AL., PROCEEDINGS OF THE NATIONAL ACADEMIC SCIENCES, U.S.A., vol. 90, 1993, pages 5873 - 5877, Retrieved from the Internet <URL:http://wwwncbi.nlm.nih.gov/BLAST> |
KAWANISHI H. ET AL.: "Saibo Baiyo Josei no Proteome Kaiseki ni yoru Nyoro Johi Saibo Zoshoku Inshi no Dotei", DAI 64 KAI ANNUAL MEETING OF THE JAPAN CANCER ASSOCIATION KIJI, no. 60), 15 August 2005 (2005-08-15), pages 292, PA2, XP003010022 * |
MUELLER S.G. ET AL.: "Melanoma growth stimulatory activity enhances the phosphorylation of the class II interleukin-8 receptor in non-hematopoietic cells", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 3, 1994, pages 1973 - 1980, XP003008799 * |
PEARSON, W. R. ET AL., PROCEEDINGS OF THE NATIONAL ACADEMIC SCIENCES, U.S.A., vol. 85, 1988, pages 2444 - 2448 |
R. G SOSNOWSKI ET AL., PROCEEDINGS OF THE NATIONAL ACADEMIC SCIENCES, U.S.A., vol. 94, 1997, pages 1119 - 1123 |
RICHMOND, A. ET AL., EMBO JOURNAL, vol. 7, 1988, pages 2025 - 712033 |
SAMBROOK, J.; RUSSEL, D.: "Molecular Cloning, A LABORATORY MANUAL", vol. 1, 2, 15 January 2001, COLD SPRING HARBOR LABORATORY PRESS, pages: 7.42 - 7.45,8.9 |
SCRIVEN, S. D. ET AL., JOURNAL OF UROLOGY, vol. 158, 1997, pages 1147 - 1152 |
TACHIBANA M.: "Cytokine to Gan no Zoshoku", HUMAN CELL, vol. 8, no. 4, 22 January 1996 (1996-01-22), pages 215 - 216, XP003010023 * |
TADROS Y. ET AL.: "In vivo proteomic analysis of cytokine expression in laser capture-microdissected urothelial cells of obstructed ureteropelvic junction procured by laparoscopic dismembered pyeloplasty", JOURNAL OF ENDOUROLOGY, vol. 17, no. 5, 2003, pages 333 - 336, XP003010020 * |
Z. GUO ET AL., NUCLEIC. ACIDS. RESEARCH, vol. 22, 1994, pages 5456 - 5465 |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103408664B (zh) * | 2008-10-31 | 2015-11-25 | 东丽株式会社 | 抗人cxcl1单克隆抗体或其片段 |
CN103483450B (zh) * | 2008-10-31 | 2015-11-25 | 东丽株式会社 | 抗人cxcl1单克隆抗体或其片段 |
JP5941615B2 (ja) * | 2008-10-31 | 2016-06-29 | 東レ株式会社 | ヒトcxcl1タンパク質の免疫学的測定方法 |
US9309312B2 (en) | 2008-10-31 | 2016-04-12 | Toray Industries, Inc. | Immunoassay method for human CXCL1 protein |
CN102245767B (zh) * | 2008-10-31 | 2013-09-18 | 东丽株式会社 | 人cxcl1蛋白质的免疫学测定方法 |
CN103408664A (zh) * | 2008-10-31 | 2013-11-27 | 东丽株式会社 | 抗人cxcl1单克隆抗体或其片段 |
KR20110090985A (ko) | 2008-10-31 | 2011-08-10 | 도레이 카부시키가이샤 | 인간 cxcl1 단백질의 면역학적 측정 방법 |
CN103408663B (zh) * | 2008-10-31 | 2016-01-27 | 东丽株式会社 | 抗人cxcl1单克隆抗体或其片段 |
CN103408663A (zh) * | 2008-10-31 | 2013-11-27 | 东丽株式会社 | 抗人cxcl1单克隆抗体或其片段 |
WO2010050554A1 (ja) | 2008-10-31 | 2010-05-06 | 東レ株式会社 | ヒトcxcl1タンパク質の免疫学的測定方法 |
CN103483450A (zh) * | 2008-10-31 | 2014-01-01 | 东丽株式会社 | 抗人cxcl1单克隆抗体或其片段 |
US8741575B2 (en) | 2010-03-05 | 2014-06-03 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Methods of predicting high grade gliomas using senescence associated genes |
WO2011109810A3 (en) * | 2010-03-05 | 2012-03-01 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Methods of predicting high grade gliomas using senescence associated genes |
WO2011109810A2 (en) * | 2010-03-05 | 2011-09-09 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Methods of predicting high grade gliomas using senescence associated genes |
WO2020071489A1 (ja) * | 2018-10-04 | 2020-04-09 | 国立大学法人大阪大学 | 尿路上皮がんを検査する方法 |
Also Published As
Publication number | Publication date |
---|---|
ATE462803T1 (de) | 2010-04-15 |
EP1930445A1 (en) | 2008-06-11 |
JP5078015B2 (ja) | 2012-11-21 |
CA2621060A1 (en) | 2007-03-08 |
JPWO2007026895A1 (ja) | 2009-03-12 |
CN101297046B (zh) | 2013-01-02 |
DE602006013333D1 (de) | 2010-05-12 |
EP1930445A4 (en) | 2008-12-10 |
KR20080046693A (ko) | 2008-05-27 |
US20100009347A1 (en) | 2010-01-14 |
US7910316B2 (en) | 2011-03-22 |
EP1930445B1 (en) | 2010-03-31 |
CN101297046A (zh) | 2008-10-29 |
ES2343276T3 (es) | 2010-07-27 |
KR101393144B1 (ko) | 2014-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5078015B2 (ja) | 尿路上皮ガンの検出用キットおよび方法 | |
KR101828290B1 (ko) | 자궁내막암 마커 | |
US20140099310A1 (en) | Cancer targets and uses thereof | |
JP2004198419A (ja) | Timp1を用いた検出方法 | |
WO2006078911A2 (en) | Gitr antibodies for the diagnosis of nsclc | |
US20140357518A1 (en) | Methods and Compositions for the Treatment and Diagnosis of Thyroid Cancer | |
JP2002512513A (ja) | 胃腸管の疾患の検出に有用な試薬および方法 | |
JP2012531606A (ja) | Δ133p53βを用いた転移癌を有する素因があると思われる被験体の検査方法 | |
WO2005042102A1 (en) | A protein involved in ovarian cancer | |
US9056919B2 (en) | USP2a peptides and antibodies | |
KR100679666B1 (ko) | 인간 대식세포 억제 사이토카인-1 특이적 단일클론항체,이를 분비하는 하이브리도마 및 이를 포함하는 위암 진단키트 | |
WO2006013474A2 (en) | Ppgalnac-t6 mrna or peptide as a new marker for detection cancer cells | |
JP4705469B2 (ja) | 抗bambi抗体、及びそれを含有する大腸癌及び肝臓癌の診断剤又は治療剤 | |
JP2012018119A (ja) | 大腸癌検出用マーカーおよびそれを用いた大腸癌検出方法 | |
WO2006078780A2 (en) | Rdc1 antibodies for the diagnosis of nsclc | |
JP2009065969A (ja) | 胃ガン腹腔内転移判定用組成物及び方法 | |
WO2009077157A1 (en) | Method for colorectal tumor diagnosis | |
JP2009065969A5 (ja) | ||
JP2009121874A (ja) | 消化器癌の診断方法 | |
MX2007008691A (en) | Gitr antibodies for the diagnosis of nsclc | |
KR20150012090A (ko) | 항-안지오포이에틴 2 항체에 대한 임상 마커 및 이의 이용 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680039458.1 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2007533367 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11991184 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2621060 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006797321 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087007943 Country of ref document: KR |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) |